Featured Research

from universities, journals, and other organizations

Economic analysis: Erlotinib marginally cost-effective

Date:
February 16, 2010
Source:
Journal of the National Cancer Institute
Summary:
Weighing both magnitude of survival benefit and expense, researchers found that the drug erlotinib, which was found to improve overall survival by 2 months in patients with advanced non-small cell lung cancer, is marginally cost-effective.

Weighing both magnitude of survival benefit and expense, researchers found that the drug erlotinib, which was found to improve overall survival by 2 months in patients with advanced non-small cell lung cancer, is marginally cost-effective. The results of their economic analysis using clinical trial data were reported in a new study published online February 16 in the Journal of the National Cancer Institute.

Related Articles


Natasha B. Leighl, M.D., of the University Health Network in Toronto, Canada, and colleagues performed an analysis of erlotinib treatment in the NCIC Clinical Trials Group BR.21 trial to determine the cost-effectiveness of treating various populations with the drug, a tyrosine kinase inhibitor. The researchers also calculated the incremental cost-effectiveness ratio.

The incremental cost-effectiveness ratio for erlotinib treatment in the trial population was $94,638 (2007 Canadian dollar) per life-year gained (95% confidence interval = $52,359 to $429,148).

According to the researchers, this figure exceeds the threshold historically accepted as cost-effective ($50,000 per quality-adjusted life year). The ratio was in the higher range of cost-effectiveness ratios that high-resource countries may consider acceptable. Thus, it may be possible to enhance the cost-effectiveness of this treatment through the clinical and molecular selection of patients for treatment, the authors report.

Subgroup analyses revealed that erlotinib may be more cost-effective in never-smokers or patients with high EGFR gene copy number.

"Ongoing efforts to identify which patients are most likely to benefit from treatment and to make targeted cancer therapies more affordable will serve to make this important treatment option available for lung cancer patients worldwide," the authors write.

In an accompanying editorial, Scott D. Ramsey, M.D., Ph.D., of Fred Hutchinson Cancer Research Center, in Seattle, said the study provided new information to help address some of the questions surrounding the drug's use. Although the study's findings are unlikely to sway any policies, it does provide information on the potential economic impact of biomarker-guided treatment with erlotinib.

"The unwillingness of public and private health systems and providers in the United States to consider costs relative to benefits in decisions about access to these products presents a clear signal to drug manufacturers," he writes. "It also presents the rest of the world with a need for information that identifies patients for whom the amount of benefit of therapies such as erlotinib can support a valid argument for their use."


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Bradbury et al. Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non-Small Cell Lung Cancer. Journal of the National Cancer Institute, 2010; DOI: 10.1093/jnci/djp518

Cite This Page:

Journal of the National Cancer Institute. "Economic analysis: Erlotinib marginally cost-effective." ScienceDaily. ScienceDaily, 16 February 2010. <www.sciencedaily.com/releases/2010/02/100216163334.htm>.
Journal of the National Cancer Institute. (2010, February 16). Economic analysis: Erlotinib marginally cost-effective. ScienceDaily. Retrieved February 27, 2015 from www.sciencedaily.com/releases/2010/02/100216163334.htm
Journal of the National Cancer Institute. "Economic analysis: Erlotinib marginally cost-effective." ScienceDaily. www.sciencedaily.com/releases/2010/02/100216163334.htm (accessed February 27, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, February 27, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Sleeping Too Much Or Too Little Might Increase Stroke Risk

Sleeping Too Much Or Too Little Might Increase Stroke Risk

Newsy (Feb. 26, 2015) People who sleep more than eight hours per night are 45 percent more likely to have a stroke, according to a University of Cambridge study. Video provided by Newsy
Powered by NewsLook.com
London Show Dissects History of Forensic Science

London Show Dissects History of Forensic Science

AFP (Feb. 25, 2015) Forensic science, which has fascinated generations with its unravelling of gruesome crime mysteries, is being put under the microscope in an exhibition of real criminal investigations in London. Duration: 00:53 Video provided by AFP
Powered by NewsLook.com
Michigan Couple Celebrates Identical Triplets

Michigan Couple Celebrates Identical Triplets

AP (Feb. 25, 2015) A suburban Detroit couple who have two older children are adjusting to life after becoming parents to identical triplets _ a multiple birth a doctor calls rare. (Feb. 25) Video provided by AP
Powered by NewsLook.com
Mayor Says District of Columbia to Go Ahead With Pot Legalization

Mayor Says District of Columbia to Go Ahead With Pot Legalization

Reuters - News Video Online (Feb. 25, 2015) Washington&apos;s mayor says the District of Columbia will move forward with marijuana legalization, despite pushback from Congress. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins